Thompson Davis & Co’s Krystal Biotech KRYS Stock Holding History

Thompson Davis & Co’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100	Closed	-$1K	–	758
2018 Q2	$1K	Buy	+100	New	+$1.13K	﹤0.01%	647

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SST

S Squared Technology New York $264M AUM 73.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thompson Davis & Co's KRYS Position: Q3 2018 in Review

Thompson Davis & Co sold out of Krystal Biotech (KRYS) in Q3 2018, closing a stake of 100 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in KRYS in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 23 funds tracked by Wall St. Rank hold KRYS as of Q3 2018.

Thompson Davis & Co reported no remaining Krystal Biotech position as of Q3 2018 after selling out during the quarter.
Thompson Davis & Co sold 100 Krystal Biotech shares in Q3 2018, an estimated $1K.
Thompson Davis & Co first reported a position in Krystal Biotech in Q2 2018 and held it in 1 quarter.
Thompson Davis & Co's Krystal Biotech position peaked at $1K in Q2 2018.
23 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.